{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=29",
    "query": {
      "condition": "Metabolic Abnormalities",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 2426,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Abnormalities&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T18:38:02.860Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT00688597",
      "title": "Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Duvoglustat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-12-08",
      "completion_date": "2009-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688597"
    },
    {
      "nct_id": "NCT06465810",
      "title": "Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transthyretin Amyloidosis",
        "ATTR-CM",
        "ATTRv-PN",
        "ATTR",
        "ATTR-Mixed",
        "hATTR"
      ],
      "interventions": [
        {
          "name": "Treatment of transthyretin (ATTR) amyloidosis in observational study setting",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1850,
      "start_date": "2024-06-25",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 33,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 24 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465810"
    },
    {
      "nct_id": "NCT02175004",
      "title": "Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "FAP",
        "Familial Amyloid Polyneuropathy",
        "TTR",
        "Transthyretin",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Inotersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2014-06-26",
      "completion_date": "2021-01-07",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 9,
      "location_summary": "Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175004"
    },
    {
      "nct_id": "NCT03614234",
      "title": "Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "pegunigalsidase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2018-11-13",
      "completion_date": "2026-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03614234"
    },
    {
      "nct_id": "NCT03811028",
      "title": "A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sanfilippo Syndrome Type A (MPS IIIA)"
      ],
      "interventions": [
        {
          "name": "SOBI003",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "78 Months",
        "sex": "ALL",
        "summary": "18 Months to 78 Months"
      },
      "enrollment_count": 6,
      "start_date": "2019-01-19",
      "completion_date": "2021-05-07",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03811028"
    },
    {
      "nct_id": "NCT07531251",
      "title": "Clinical Trial in Patients With Barth Syndrome- 4TAZPower",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Barth Syndrome"
      ],
      "interventions": [
        {
          "name": "Elamipretide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "5 Years to 55 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2026-07-02",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 1,
      "location_summary": "Needham, Massachusetts",
      "locations": [
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07531251"
    },
    {
      "nct_id": "NCT00418795",
      "title": "Porphozym in the Treatment of Acute Attacks in AIP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute Intermittent Porphyria"
      ],
      "interventions": [
        {
          "name": "recombinant human porphobilinogen deaminase (Porphozym)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zymenex A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2003-06-11",
      "completion_date": "2006-06-20",
      "has_results": false,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00418795"
    },
    {
      "nct_id": "NCT01465165",
      "title": "Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Paul Carlson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2011-05-15",
      "completion_date": "2012-06-24",
      "has_results": false,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465165"
    },
    {
      "nct_id": "NCT00002095",
      "title": "A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 700,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-30T18:38:02.860Z",
      "location_count": 19,
      "location_summary": "Berkeley, California • Los Angeles, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002095"
    }
  ]
}